Clinical pharmacokinetics of theophylline during co-treatment with ticarcillin plus clavulanic acid in patients suffering from acute exacerbation of chronic bronchitis

J Chemother. 1993 Aug;5(4):233-6. doi: 10.1080/1120009x.1993.11739238.

Abstract

The effect of ticarcillin/clavulanic acid, taken for 7 days as vials containing 1000 mg of ticarcillin and 200 mg of clavulanic acid twice daily intramuscularly, on the steady-state pharmacokinetics of theophylline was studied in 12 patients suffering from acute exacerbation of chronic obstructive pulmonary disease. Initially, patients were treated for four days with theophylline as sustained-release formulation in the amount of 600 mg daily; on the last day, blood samples were taken for theophylline determination. Theophylline concentrations were measured serially for 12 hours by the method of polarized immunofluorescence (Abbott TDx system). Subsequently, while theophylline was continued at the same dosage, each patient received in addition ticarcillin/clavulanic acid vials every 12 hours. After seven days of this combined medication, the serial assays of plasma were repeated at the same time intervals as before. No influence of ticarcillin/clavulanic acid was detectable on the steady-state theophylline pharmacokinetics. It is concluded that both drugs can be administered concomitantly without any dosage adjustment of theophylline.

Publication types

  • Clinical Trial

MeSH terms

  • Bronchitis / drug therapy*
  • Bronchitis / metabolism*
  • Bronchitis / microbiology
  • Clavulanic Acids / therapeutic use*
  • Drug Therapy, Combination / therapeutic use
  • Humans
  • Lung Diseases, Obstructive / drug therapy
  • Theophylline / blood
  • Theophylline / pharmacokinetics*
  • Ticarcillin / therapeutic use*
  • beta-Lactamase Inhibitors

Substances

  • Clavulanic Acids
  • beta-Lactamase Inhibitors
  • ticarcillin-clavulanic acid
  • Theophylline
  • Ticarcillin